4th Quarter - Termination

THE ADVOCACY GROUP for EMERGENT BIOSOLUTIONS

Firm
Client
Income
$30,000
Expenses
—
Terminated
Dec 31, 2018

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
4th Quarter - Report Jan 17, 2019 $30,000 Replaced
4th Quarter - Termination (this page) Mar 4, 2019 $30,000 Yes

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

FDA regulatory issues Issues related to Priority Review Voucher programs Opioid and heroin addiction legislation, Naloxone access, coprescribing / opioid prescribing

LobbyistCovered position, as disclosed
ROBERT J DOTCHIN —

Contacted: Homeland Security, Dept of (DHS); HOUSE OF REPRESENTATIVES; SENATE

Budget/Appropriations BUD

FY 2019 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government Re-authorization of the Pandemic and All-Hazards Preparedness Act Department of Defense appropriations for Medical Countermeasures

LobbyistCovered position, as disclosed
ROBERT J DOTCHIN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Homeland Security, Dept of (DHS)

Homeland Security HOM

HR 6378, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018

LobbyistCovered position, as disclosed
ROBERT J DOTCHIN —

Contacted: Homeland Security, Dept of (DHS); HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 6378 (115th)

Defense DEF

NDAA - provisions related to biological and chemical defense

LobbyistCovered position, as disclosed
ROBERT J DOTCHIN —

Contacted: SENATE; Homeland Security, Dept of (DHS); HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.